Free Trial
NYSEARCA:XBI

SPDR S&P Biotech ETF (XBI) Price, Holdings, & News

SPDR S&P Biotech ETF logo
$76.39 -1.65 (-2.11%)
As of 05/9/2025 04:10 PM Eastern

About SPDR S&P Biotech ETF (NYSEARCA:XBI)

Key Stats

Today's Range
$76.30
$79.55
50-Day Range
$69.80
$88.82
52-Week Range
$66.66
$105.47
Volume
11.44 million shs
Average Volume
9.07 million shs
Market Capitalization
$4.85 billion
Assets Under Management
$4.81 billion
Dividend Yield
0.18%
Net Expense Ratio
0.35%
Aggregate Rating
Moderate Buy

ETF Overview

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor.

SPDR S&P Biotech ETF Expenses

TypeXBIHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFs
Management Fee0.35%0.57%0.57%0.52%0.53%
Other Expenses0.00%0.30%0.48%0.56%0.52%
Total Expense0.35%0.70%0.72%0.73%0.71%
Fee Waiver0.00%-0.45%-0.49%-0.65%-0.54%
Net Expense0.35%0.61%0.63%0.58%0.60%
Receive XBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SPDR S&P Biotech ETF and its competitors with MarketBeat's FREE daily newsletter.

XBI ETF News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
SPDR S&P Biotech ETF Experiences Big Inflow
Friday's ETF Movers: XBI, COPX
See More Headlines

XBI ETF - Frequently Asked Questions

SPDR S&P Biotech ETF's stock was trading at $90.06 on January 1st, 2025. Since then, XBI shares have decreased by 15.2% and is now trading at $76.39.
View the best growth stocks for 2025 here
.

Top institutional investors of SPDR S&P Biotech ETF include Goldman Sachs Group Inc. (21.29%), Demars Financial Group LLC (4.94%), Bessemer Group Inc. (2.25%) and Migdal Insurance & Financial Holdings Ltd. (1.65%).

Shares of XBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that SPDR S&P Biotech ETF investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), DiamondRock Hospitality (DRH) and Humana (HUM).

Fund Details

Issuer
SSgA
Fund Name
SPDR S&P Biotech ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NYSEARCA
Current Symbol
NYSEARCA:XBI
Inception Date
1/31/2006
Fund Manager
Michael Feehily, Karl Schneider, Raymond Donofrio

Fund Focus

Asset Class
Equity
Benchmark
S&P Biotech Index
Category
Sector
Focus
Health Care
Development Level
Developed Markets
Region
North America
Number of Holdings
149

Fund Statistics

Assets Under Management
$4.81 billion
Average Daily Volume
$13.76 million
Discount/Premium
0.05%

Administrator, Advisor and Custodian

Administrator
SSgA Funds Management, Inc.
Advisor
SSgA Funds Management, Inc.
Custodian
State Street Bank and Trust Company
Distributor
State Street Global Advisors Funds Distributors, LLC
Transfer Agent
State Street Bank and Trust Company
Trustee
N/A
Lead Market Maker
Virtu Financial

Options

Optionable
Optionable
Options Volume
84,639
Put Options
54,747
Call Options
29,892
Short Interest
66,410,000 shs

Miscellaneous

Beta
1.00
Creation Unit
50,000
Creation Fee
$250.00
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Top 10 XBI Holdings

XBI Sector Exposure

XBI Industry Exposure


This page (NYSEARCA:XBI) was last updated on 5/10/2025 by MarketBeat.com Staff
From Our Partners